Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF 15 activity in the subject.


The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.


The invention provides methods and compositions of treating a subject having a cardiac- related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF 15 activity in the subject.


The invention provides methods and compositions for treating a subject having a renal- related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.


A test to identify whether a lung patient is likely to benefit from combination therapy in the form of an epidermal growth factor receptor inhibitor (EGFR-I) and a monoclonal antibody drug targeting hepatocyte growth factor (HGF) as compared to EGFR-I monotherapy. The test makes use of a mass spectrum obtained from a serum or plasma sample and a computer configured as a classifier operating on the mass spectrum and a training set in the form of class-labeled mass spectra from other cancer patients. The computer classifier executes a classification algorithm, such as K-nearest neighbor, and assigns a class label to the serum or plasma sample. Samples classified as Poor or the equivalent are associated with patients which are likely to benefit from the combination therapy more than from EGFR-I monotherapy. The invention also includes improved methods of treating patients predicted by the test.


Patent
AVEO Pharmaceuticals | Date: 2016-01-04

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.


Patent
AVEO Pharmaceuticals | Date: 2015-09-24

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.


Patent
AVEO Pharmaceuticals | Date: 2013-12-20

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.


Patent
AVEO Pharmaceuticals | Date: 2013-11-01

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur dOrigine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.


Patent
AVEO Pharmaceuticals | Date: 2013-08-05

A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.

Loading AVEO Pharmaceuticals collaborators
Loading AVEO Pharmaceuticals collaborators